Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2022 Jun 8:ciac439. doi: 10.1093/cid/ciac439

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Nathaniel M Lewis 1,, Wesley H Self 2, Manjusha Gaglani 3,4, Adit A Ginde 5, David J Douin 6, H Keipp Talbot 7, Jonathan D Casey 8, Nicholas M Mohr 9, Anne Zepeski 10, Shekhar A Ghamande 11, Tresa A McNeal 12, Nathan I Shapiro 13, Kevin W Gibbs 14, D Clark Files 15, David N Hager 16, Arber Shehu 17, Matthew E Prekker 18, Heidi L Erickson 19, Michelle N Gong 20, Amira Mohamed 21, Nicholas J Johnson 22, Vasisht Srinivasan 23, Jay S Steingrub 24, Ithan D Peltan 25, Samuel M Brown 26, Emily T Martin 27, Arnold S Monto 28, Akram Khan 29, Laurence W Busse 30, Caitlin C ten Lohuis 31, Abhijit Duggal 32, Jennifer G Wilson 33, Alexandra June Gordon 34, Nida Qadir 35, Steven Y Chang 36, Christopher Mallow 37, Carolina Rivas 38, Hilary M Babcock 39, Jennie H Kwon 40, Matthew C Exline 41, Adam S Lauring 42, Natasha Halasa 43, James D Chappell 44, Carlos G Grijalva 45, Todd W Rice 46, Jillian P Rhoads 47, Ian D Jones 48, William B Stubblefield 49, Adrienne Baughman 50, Kelsey N Womack 51, Christopher J Lindsell 52, Kimberly W Hart 53, Yuwei Zhu 54, Katherine Adams 55, Manish M Patel 56, Mark W Tenforde 57; IVY Network Collaborators
PMCID: PMC9214149  PMID: 35675695

Abstract

Background

Adults in the United States (US) began receiving the viral vector COVID-19 vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use.

Methods

In a multicenter case-control analysis of US adults (≥18 years) hospitalized March 11–December 15, 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression.

Results

After excluding patients receiving mRNA vaccines, among 3,979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2.229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% CI: 63%–75%) overall, including 55% (29%–72%) among immunocompromised patients, and 72% (64%–77%) among immunocompetent patients, for whom VEs was similar at 14–90 days (73% [59%–82%]), 91–180 days (71% [60%–80%]), and 181–274 days (70% [54%–81%]) post-vaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18%–65%) among immunocompetent patients.

Conclusions

The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months post-vaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.

Keywords: COVID-19, vaccine effectiveness, viral vector vaccines

Contributor Information

Nathaniel M. Lewis, CDC COVID-19 Response Team, Atlanta, GA, USA.

Wesley H. Self, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Manjusha Gaglani, Baylor Scott & White Health, Temple, Texas, USA; Texas A&M University College of Medicine, Temple, Texas, USA.

Adit A. Ginde, University of Colorado School of Medicine, Aurora, Colorado, USA.

David J. Douin, University of Colorado School of Medicine, Aurora, Colorado, USA.

H. Keipp Talbot, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Jonathan D. Casey, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Nicholas M. Mohr, University of Iowa, Iowa City, Iowa, USA.

Anne Zepeski, University of Iowa, Iowa City, Iowa, USA.

Shekhar A. Ghamande, Baylor Scott & White Health, Temple, Texas, USA.

Tresa A. McNeal, Baylor Scott & White Health, Temple, Texas, USA.

Nathan I. Shapiro, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Kevin W. Gibbs, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA.

D. Clark Files, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA.

David N. Hager, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Arber Shehu, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Matthew E. Prekker, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

Heidi L. Erickson, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

Michelle N. Gong, Montefiore Healthcare Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Amira Mohamed, Montefiore Healthcare Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Nicholas J. Johnson, University of Washington School of Medicine, Seattle, Washington, USA.

Vasisht Srinivasan, University of Washington School of Medicine, Seattle, Washington, USA.

Jay S. Steingrub, Baystate Medical Center, Springfield, Massachusetts, USA.

Ithan D. Peltan, Intermountain Medical Center and University of Utah, Salt Lake City, Utah, USA.

Samuel M. Brown, Intermountain Medical Center and University of Utah, Salt Lake City, Utah, USA.

Emily T. Martin, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Arnold S. Monto, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Akram Khan, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Laurence W. Busse, Emory University School of Medicine, Atlanta, Georgia, USA.

Caitlin C. ten Lohuis, Emory University School of Medicine, Atlanta, Georgia, USA.

Abhijit Duggal, Cleveland Clinic, Cleveland, Ohio, USA.

Jennifer G. Wilson, Stanford University School of Medicine, Palo Alto, California, USA.

Alexandra June Gordon, Stanford University School of Medicine, Palo Alto, California, USA.

Nida Qadir, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA.

Steven Y. Chang, David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA.

Christopher Mallow, University of Miami, Miami, Florida, USA.

Carolina Rivas, University of Miami, Miami, Florida, USA.

Hilary M. Babcock, Washington University, St. Louis, Missouri, USA.

Jennie H. Kwon, Washington University, St. Louis, Missouri, USA.

Matthew C. Exline, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Adam S. Lauring, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

Natasha Halasa, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

James D. Chappell, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Carlos G. Grijalva, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Todd W. Rice, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Jillian P. Rhoads, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Ian D. Jones, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

William B. Stubblefield, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Adrienne Baughman, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Kelsey N. Womack, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Christopher J. Lindsell, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Kimberly W. Hart, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Yuwei Zhu, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Katherine Adams, CDC COVID-19 Response Team, Atlanta, GA, USA.

Manish M. Patel, CDC COVID-19 Response Team, Atlanta, GA, USA.

Mark W. Tenforde, CDC COVID-19 Response Team, Atlanta, GA, USA.

Supplementary Material

ciac439_Supplementary_Data

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ciac439_Supplementary_Data

Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES